648.50
Schlusskurs vom Vortag:
$647.49
Offen:
$647.09
24-Stunden-Volumen:
37,921
Relative Volume:
0.15
Marktkapitalisierung:
$39.34B
Einnahmen:
$1.86B
Nettoeinkommen (Verlust:
$-40.29M
KGV:
-762.94
EPS:
-0.85
Netto-Cashflow:
$-1.28B
1W Leistung:
+1.42%
1M Leistung:
+0.17%
6M Leistung:
+23.40%
1J Leistung:
+62.14%
Argen X Se Adr Stock (ARGX) Company Profile
Vergleichen Sie ARGX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ARGX
Argen X Se Adr
|
648.71 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
480.55 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
697.47 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.07 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
117.11 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-17 | Herabstufung | Deutsche Bank | Hold → Sell |
2024-11-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2024-11-05 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
2024-11-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2024-11-01 | Hochstufung | William Blair | Mkt Perform → Outperform |
2024-10-10 | Fortgesetzt | Raymond James | Strong Buy |
2024-10-04 | Herabstufung | Deutsche Bank | Buy → Hold |
2024-08-06 | Hochstufung | Barclays | Equal Weight → Overweight |
2024-07-25 | Hochstufung | Deutsche Bank | Hold → Buy |
2024-07-23 | Hochstufung | Oppenheimer | Perform → Outperform |
2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
2023-12-20 | Herabstufung | Deutsche Bank | Buy → Hold |
2023-12-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
2023-07-31 | Eingeleitet | Scotiabank | Sector Perform |
2023-07-24 | Herabstufung | UBS | Buy → Neutral |
2023-07-17 | Fortgesetzt | Evercore ISI | Outperform |
2023-06-15 | Eingeleitet | Societe Generale | Sell |
2023-05-31 | Eingeleitet | UBS | Buy |
2023-04-25 | Eingeleitet | Citigroup | Buy |
2023-03-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2022-12-07 | Eingeleitet | William Blair | Outperform |
2022-10-12 | Eingeleitet | Oppenheimer | Perform |
2022-07-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2022-06-28 | Fortgesetzt | Stifel | Buy |
2022-05-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
2021-11-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
2021-10-29 | Hochstufung | Guggenheim | Neutral → Buy |
2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
2021-10-07 | Eingeleitet | Jefferies | Buy |
2021-09-23 | Hochstufung | Redburn | Neutral → Buy |
2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-07-23 | Eingeleitet | Deutsche Bank | Hold |
2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
2021-06-18 | Eingeleitet | UBS | Buy |
2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
2021-05-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2021-04-23 | Eingeleitet | Redburn | Neutral |
2021-03-05 | Bestätigt | H.C. Wainwright | Neutral |
2021-02-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-01-04 | Herabstufung | Guggenheim | Buy → Neutral |
2020-08-25 | Eingeleitet | Raymond James | Outperform |
2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
2020-07-29 | Eingeleitet | H.C. Wainwright | Neutral |
2020-02-10 | Eingeleitet | BofA/Merrill | Buy |
2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
2019-10-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
2019-10-22 | Eingeleitet | JP Morgan | Overweight |
2019-09-27 | Eingeleitet | Wells Fargo | Market Perform |
2019-09-16 | Fortgesetzt | Cowen | Outperform |
2019-06-28 | Eingeleitet | Robert W. Baird | Outperform |
2019-01-18 | Fortgesetzt | SunTrust | Buy |
2019-01-04 | Eingeleitet | Morgan Stanley | Overweight |
2018-12-17 | Eingeleitet | Goldman | Buy |
2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
2018-06-29 | Eingeleitet | Nomura | Buy |
2018-04-09 | Eingeleitet | SunTrust | Buy |
2018-01-29 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Argen X Se Adr Aktie (ARGX) Neueste Nachrichten
Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs - Investor's Business Daily
BBVA Argentina ADR (BBAR) Shares Rise Despite Market Challenges - The News Heater
Telecom Argentina S.A. ADR (TEO) Stock Records 32.38% Quarterly Movement - The News Heater
Guru Fundamental Report for ARGXBenjamin Graham - Nasdaq
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
argenx SE : The stock is approaching a major resistance level -January 29, 2025 at 04:11 am EST - Marketscreener.com
argenx's SWOT analysis: biotech stock soars on VYVGART success, pipeline promise - Investing.com India
Argenx stock price target raised to $717 by H.C. Wainwright - Investing.com India
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Truist Securities raises argenx stock rating to Buy, says will exceed Vision 2030 - Investing.com
Jefferies raises argenx stock target, reaffirms buy on global sales result - Investing.com
argenx's SWOT analysis: biotech stock soars on vyvgart success - Investing.com
Piper Sandler increases argenx stock price target on revised estimates - Investing.com
Argenx stock soars to all-time high of $645.31 amid robust growth - Investing.com
Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
Argenx stock soars to all-time high of $630.4 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $630.4 amid robust growth - Investing.com
argenx's SWOT analysis: biotech stock soars on VYVGART success - Investing.com
Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - MSN
Argenx Expands Autoimmune Portfolio With Additional Vyvgart Approvals as Pipeline Develops - Morningstar
Piper Sandler maintains stock target on argenx, cites growth potential - Investing.com
Argenx stock soars to all-time high of $620.29 - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Argenx stock soars to all-time high of $612.64 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $612.64 amid robust growth - Investing.com India
argenx's SWOT analysis: biotech firm's stock soars on VYVGART success - Investing.com
Jefferies reaffirms Buy rating on argenx stock, ups target amid promising trial updates - Investing.com India
Can Argenx stock sustain its autoimmune category dominance? Oppenheimer weighs in - Investing.com
Barclays bullish on argenx stock after positive trial results - Investing.com
Barclays bullish on argenx stock after positive trial results By Investing.com - Investing.com South Africa
argenx shares see price target boosted by Raymond James, Strong Buy rating upheld - Investing.com
10 Biggest Biotechnology Companies - Investopedia
Argenx upgraded at Wolfe on myasthenia gravis dominance - MSN
argenx stock boosted by Wolfe, citing dominance in MG and profitability ahead - Investing.com
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Yahoo Finance
Scotiabank raises argenx stock PT to $715, highlights efgartigimod's potential - Investing.com India
argenx SE's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Deutsche Bank raises argenx target by EUR25, acknowledges momentum despite valuation - Investing.com
argenx ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
Argenx shares target raised by H.C. Wainwright, citing strong sales performance - Investing.com
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry' - Benzinga
Finanzdaten der Argen X Se Adr-Aktie (ARGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):